ANZICS CTG Endorsed Study
Blend to Limit oxygen in ECMO: A randomised controlled registry trial
Aim: Our aim is to determine in patients requiring venoarterial (V-A) ECMO, whether the use of a conservative as compared with liberal oxygen strategy, results in improved patient outcomes.
Rationale: There is a growing body of evidence that suggests high levels of oxygen may be harmful for our patients. In ECMO patients, the fraction of oxygen in the fresh gas delivered to the membrane (FbO2) was traditionally maintained at 1.0 (or 100% O2), however, in recent years a significant number of centres (within Australia and worldwide) are titrating the FbO2 according to patients’ needs. The variation in clinical practice is a result of the lack of evidence based guidelines. Current ECMO guidelines do not specify an optimal oxygen strategy and clinical equipoise exists.
In the BLENDER Trial we will determine if using a conservative versus a liberal approach to oxygen administration improves patient outcomes. If the BLENDER Trial confirms that one oxygen management strategy is more effective than the other, its findings may improve the lives of critically ill Australians and inform clinical practice worldwide.
David Pilcher, Kelly Ottosen, Michael Bailey, Rinaldo Bellomo, Aidan Burrell, Hergen Buscher, Amanda Corley, Glen Eastwood, Paul Forrest, John Fraser, David Gattas, Lisa Higgins, Andrew Hilton, Carol Hodgson, Edward Litton, Chris Macisaac, Emma Martin, Priya Nair, Vince Pellegrino, Kiran Shekar, Tony Trapani, Andrew Udy, Marc Ziengenfuss.
ANZICS Research Centre, Monash University
MRFF- Research Grant
114 patient enrolled, Good adherence to protocol, DSMC 50 patient interim analysis completed, 10 sites on-board Australia wide, 4 Victoria, 2 New South Wales, 3 Queensland, 1 South Australia, 4 sites to come on-board pending RGO approval and site start up